Vortioxetine A new option for depression – MM1604
Vortioxetine has been approved for treatment of adults with major depressive disorder. It adds to the repertoire of antidepressants available for individualising treatment and may have particular benefits for patients with cognitive impairment associated with depression.
In vitro studies indicate that it is an inhibitor of serotonin reuptake and acts as an agonist at the serotonin 5-HT1A receptor, partial agonist at the 5-HT1B receptor and antagonist at the 5-HT1D, 5-HT3 and 5-HT7 receptors.
In adults, the usual starting dose of vortioxetine is 10mg once daily, taken with or without food at any time of day.
Modern Medicine – April 2016
